-
2023-504989-37-00
5
Metastatic Squamous Non-small Cell Lung Cancer
-
2024-519031-42-00
5
pancreatic ductal adenocarcinoma
-
2024-519655-28-00
5
Premenopausal patients with high-risk HR-positive/HER2-negative breast
-
2025-521221-32-00
5
Advanced or Metastatic Non-Small Cell Lung Cancer
-
2025-521583-35-00
4
non-small cell lung cancer (NSCLC)
-
2025-521775-31-00
5
2025-11-12
Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutations
-
2022-500273-14-00
10
2023-07-17
Atherosclerotic cardiovascular disease in patients with ESKD
-
2024-515765-34-00
5
2026-02-04
English
First-line extensive-stage small-cell lung cancer (ES-SCLC)
-
2024-517136-21-00
5
2025-12-05
Renal Cell Carcinoma
-
2025-520555-89-00
5
2025-11-14
Metastatic castration-resistant prostate cancer (mCRPC)
-
2024-518365-10-00
5
2025-10-28
Previously Untreated Advanced or Metastatic Non-Squamous Non−Small Cel
-
2024-517780-24-00
5
2025-09-18
Lung Cancer
-
2024-515884-69-00
5
2025-07-16
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
-
2024-513682-40-01
5
2025-07-04
Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer
-
2024-515764-31-00
10
2025-06-13
Non-small cell lung cancer
-
2023-506817-23-01
5
2025-05-23
Metastatic hormone naïve prostate cancer (mHNPC)
-
2024-514281-39-00
5
2025-02-14
Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD
-
2024-515008-38-00
5
2025-02-14
Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Expres
-
2024-517863-22-00
5
2024-12-01
Study population consists in patients with a diagnosis of mCRC who hav
-
2023-509340-10-00
5
2024-10-29
Patients with HLA-A2 positive phenotype and metastatic Non-Small Cell
-
2024-513087-26-00
5
2024-09-10
Metastatic Non-small Cell Lung Cancer
-
2023-509551-14-00
5
2024-06-12
Unresectable left sided RAS/B-RAF wild-type metastatic colorectal canc
-
2022-501453-36-00
5
2024-02-23
Breast cancer
-
2024-515740-23-00
5
2025-03-25
Extensive-Stage Small Cell Lung Cancer (ES-SCLC)